Benchmark Reiterates Speculative Buy Rating on Unicycive Therapeutics (UNCY)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
| (NASDAQ: UNCY) | Delayed: 3.59 +0.10 (2.87%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.49 | 52 Week High | $ | |||
| Open | $3.50 | 52 Week Low | $ | |||
| Day High | $3.64 | P/E | N/A | |||
| Day Low | $3.48 | EPS | $ | |||
| Volume | 940,807 | |||||
